<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.118528</article-id><article-id pub-id-type="publisher-id">ACM-44706</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210800000_88983279.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  长链非编码RNA在急性髓系白血病发病机制中的研究进展
  Research Progress of Long Non-Coding RNA in the Pathogenesis of Acute Myeloid Leukemia
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>何</surname><given-names>冉冉</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>葛</surname><given-names>繁梅</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>延安大学附属医院，陕西 延安</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>08</month><year>2021</year></pub-date><volume>11</volume><issue>08</issue><fpage>3610</fpage><lpage>3615</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  急性髓系白血病(AML)是造血系统恶性克隆性增殖性疾病，是一组高度异质性的疾病。目前还不清楚这种疾病的确切病因。复发的染色体畸变和基因突变与白血病的发展有关，并已在临床上用于急性髓性白血病患者的风险分层。由于AML的治愈率、生存率低，复发率高，因此探讨AML的发病机制，寻找新的肿瘤标志物和治疗靶点具有十分重要的意义。在过去的几年里，分子异常检测的快速发展给AML的预后预测和诊断带来了非常多的便利，给AML的诊断和治疗带来了有效的帮助。长链非编码RNA (long non-coding RNA, LncRNA)是长度超过200个核苷酸且不能翻译成蛋白质的RNA分子。但可以在转录前、转录和转录后水平调节其他基因的表达，从而参与多种肿瘤的发生和发展。近几年，随着对LncRNA研究的不断深入，其在急性髓系白血病中承担的角色不断被报道和证实。本文着重探讨了LncRNA CCDC26、XLOC_109948、LncRNA NEAT1、LncRNA-CRNDE、HOXBAS3、LncRNA CCAT1、LncRNA CASC15等长链非编码RNA在急性髓系白血病中的研究，综述了以上七种长链非编码RNA与急性髓系白血病的关系，可为急性髓系白血病的临床诊断和治疗提供潜在依据。
   Acute myeloid leukemia (AML) is a malignant clonal proliferative disease of the hematopoietic system and a group of highly heterogeneous diseases. The exact cause of this disease is still unclear. Recurring chromosomal aberrations and gene mutations are related to the development of leukemia, and have been clinically used for risk stratification of patients with acute myeloid leukemia. Due to the low cure rate, survival rate, and high recurrence rate of AML, it is of great significance to explore the pathogenesis of AML and find new tumor markers and therapeutic targets. In the past few years, the rapid development of molecular abnormality detection has brought a lot of convenience to the prognosis prediction and diagnosis of AML, and has brought effective help to the diagnosis and treatment of AML. Long non-coding RNA (LncRNA) is an RNA molecule that is more than 200 nucleotides in length and cannot be translated into protein. However, it can regulate the expression of other genes at the pre-transcription, transcription and post-transcriptional levels, thereby participating in the occurrence and development of a variety of tumors. In recent years, with the deepening of LncRNA research, its role in acute myeloid leukemia has been continuously reported and confirmed. This article focuses on the research of LncRNA CCDC26, XLOC_109948, LncRNA NEAT1, LncRNA-CRNDE, HOXBAS3, LncRNA CCAT1, LncRNA CASC15 and other long-chain non-coding RNAs in acute myeloid leukemia, and summarizes the above seven long-chain non-coding RNAs. The relationship between RNA and acute myeloid leukemia can provide a potential basis for the clinical diagnosis and treatment of acute myeloid leukemia.
 
</p></abstract><kwd-group><kwd>急性髓系白血病，长链非编码RNA，转录, Acute Myeloid Leukemia</kwd><kwd> Long Non-Coding RNA</kwd><kwd> Transcription</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>急性髓系白血病(AML)是造血系统恶性克隆性增殖性疾病，是一组高度异质性的疾病。目前还不清楚这种疾病的确切病因。复发的染色体畸变和基因突变与白血病的发展有关，并已在临床上用于急性髓性白血病患者的风险分层。由于AML的治愈率、生存率低，复发率高，因此探讨AML的发病机制，寻找新的肿瘤标志物和治疗靶点具有十分重要的意义。在过去的几年里，分子异常检测的快速发展给AML的预后预测和诊断带来了非常多的便利，给AML的诊断和治疗带来了有效的帮助。长链非编码RNA (long non-coding RNA, LncRNA)是长度超过200个核苷酸且不能翻译成蛋白质的RNA分子。但可以在转录前、转录和转录后水平调节其他基因的表达，从而参与多种肿瘤的发生和发展。近几年，随着对LncRNA研究的不断深入，其在急性髓系白血病中承担的角色不断被报道和证实。本文着重探讨了LncRNA CCDC26、XLOC_109948、LncRNA NEAT1、LncRNA-CRNDE、HOXBAS3、LncRNA CCAT1、LncRNA CASC15等长链非编码RNA在急性髓系白血病中的研究，综述了以上七种长链非编码RNA与急性髓系白血病的关系，可为急性髓系白血病的临床诊断和治疗提供潜在依据。</p></sec><sec id="s2"><title>关键词</title><p>急性髓系白血病，长链非编码RNA，转录</p></sec><sec id="s3"><title>Research Progress of Long Non-Coding RNA in the Pathogenesis of Acute Myeloid Leukemia<sup> </sup></title><p>Ranran He, Fanmei Ge</p><p>The Affiliated Hospital of Yan’an University, Yan’an Shaanxi</p><p><img src="//html.hanspub.org/file/45-1572477x4_hanspub.png?20210823171755923" /></p><p>Received: Jul. 18<sup>th</sup>, 2021; accepted: Aug. 7<sup>th</sup>, 2021; published: Aug. 23<sup>rd</sup>, 2021</p><p><img src="//html.hanspub.org/file/45-1572477x5_hanspub.png?20210823171755923" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Acute myeloid leukemia (AML) is a malignant clonal proliferative disease of the hematopoietic system and a group of highly heterogeneous diseases. The exact cause of this disease is still unclear. Recurring chromosomal aberrations and gene mutations are related to the development of leukemia, and have been clinically used for risk stratification of patients with acute myeloid leukemia. Due to the low cure rate, survival rate, and high recurrence rate of AML, it is of great significance to explore the pathogenesis of AML and find new tumor markers and therapeutic targets. In the past few years, the rapid development of molecular abnormality detection has brought a lot of convenience to the prognosis prediction and diagnosis of AML, and has brought effective help to the diagnosis and treatment of AML. Long non-coding RNA (LncRNA) is an RNA molecule that is more than 200 nucleotides in length and cannot be translated into protein. However, it can regulate the expression of other genes at the pre-transcription, transcription and post-transcriptional levels, thereby participating in the occurrence and development of a variety of tumors. In recent years, with the deepening of LncRNA research, its role in acute myeloid leukemia has been continuously reported and confirmed. This article focuses on the research of LncRNA CCDC26, XLOC_109948, LncRNA NEAT1, LncRNA-CRNDE, HOXBAS3, LncRNA CCAT1, LncRNA CASC15 and other long-chain non-coding RNAs in acute myeloid leukemia, and summarizes the above seven long-chain non-coding RNAs. The relationship between RNA and acute myeloid leukemia can provide a potential basis for the clinical diagnosis and treatment of acute myeloid leukemia.</p><p>Keywords:Acute Myeloid Leukemia, Long Non-Coding RNA, Transcription</p><disp-formula id="hanspub.44706-formula14"><graphic xlink:href="//html.hanspub.org/file/45-1572477x6_hanspub.png?20210823171755923"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/45-1572477x7_hanspub.png?20210823171755923" /> <img src="//html.hanspub.org/file/45-1572477x8_hanspub.png?20210823171755923" /></p></sec><sec id="s5"><title>1. 引言</title><p>急性髓系白血病(AML)是造血系统恶性克隆性增殖性疾病，是一组高度异质性的疾病。目前还不清楚这种疾病的确切病因。长链非编码RNA (long non-coding RNA, LncRNA)是长度超过200个核苷酸且不能翻译成蛋白质的RNA分子。LncRNA通过表观遗传、转录和转录后水平调节其他基因的表达，一些LncRNA甚至可以直接编码蛋白质，从而参与调节机体的各种生理和病理过程，包括各种恶性肿瘤的发生。近几年，随着对LncRNA研究的不断深入，其在急性髓系白血病中承担的角色不断被报道和证实。</p></sec><sec id="s6"><title>2. 长链非编码RNA</title><p>长链非编码RNA (long non-coding RNAs, LncRNAs)是长度超过200 bp的核苷酸分子，不编码或者很少编码蛋白质 [<xref ref-type="bibr" rid="hanspub.44706-ref1">1</xref>]。随着高通量测序技术和芯片检测技术的大规模应用，在肿瘤组织和体液中发现了大量的LncRNA。它们作为肿瘤促癌基因或者抑癌基因在肿瘤的发生和发展中起着至关重要的作用。LncRNA可通过转录前、转录和转录后等多种方式调控基因的表达，从而参与调节生命活动 [<xref ref-type="bibr" rid="hanspub.44706-ref2">2</xref>]。许多研究表明LncRNA对靶基因的调控作用机制有很多，如靶标诱饵或模仿：LncRNA可以欺骗另一种RNA或蛋白质，使其远离天然的靶标；调控下游基因转录，且编码上游基因；通过mRNA加工和编码基因序列之间的互补干扰；通过抑制RNA聚合酶II或染色质重塑影响基因表达；通过形成核酸–蛋白质复合物来调节蛋白质的活性；改变蛋白质细胞的位置等多种途径 [<xref ref-type="bibr" rid="hanspub.44706-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.44706-ref4">4</xref>]。</p></sec><sec id="s7"><title>3. 急性髓系白血病</title><p>急性髓系白血病(Acute myeloid leukemia, AML)是造血系统恶性克隆性增殖性疾病，是一组高度异质性的疾病。发病时骨髓中异常的原始细胞及偏原始的幼稚细胞(白血病细胞)大量增殖并抑制正常造血，浸润肝、脾、淋巴结、皮肤黏膜等器官。在正常髓系细胞发育的不同阶段，造血干细胞均可发生恶性转化。目前，我国仍沿用20世纪70年代法英美的分类标准。(France, America, Britain, FAB)分型方法对AML进行初步诊断分型。在急性髓系白血病中，LncRNA是微阵列检测到的生物标志物中的重要组成部分。它的表达可以区分急性白血病的分子亚型，为白血病分型和患者分层提供了更精确的工具 [<xref ref-type="bibr" rid="hanspub.44706-ref5">5</xref>]。近几十年来，越来越多的研究揭示了LncRNAs在包括血液系统恶性肿瘤在内的多种癌症中的关键作用。因此，了解它们的生物学过程可能会增加这些分子作为生物标志物在这些疾病的分型、诊断和治疗中的潜在应用。</p></sec><sec id="s8"><title>4. 与急性髓系白血病相关的部分LncRNA</title><sec id="s8_1"><title>4.1. LncRNA CCDC26</title><p>LncRNA CCDC26 (基因ID：137196)，位于染色体8q24上，在灵长类动物中保守。全基因组分析显示CCDC26与低水平胶质瘤相关 [<xref ref-type="bibr" rid="hanspub.44706-ref6">6</xref>]。CCDC26扩增也被认为是一种反复出现的异常，与急性髓细胞白血病对维甲酸诱导分化的反应有关 [<xref ref-type="bibr" rid="hanspub.44706-ref7">7</xref>]。WeiPeng等 [<xref ref-type="bibr" rid="hanspub.44706-ref8">8</xref>] 发现CCDC26在胰腺癌组织中的表达明显高于正常组织，下调CCDC26的表达可明显促进细胞生长停滞和凋亡。表明CCDC26可作为胰腺癌的鉴别诊断标志物。CUNTE CHEN等 [<xref ref-type="bibr" rid="hanspub.44706-ref9">9</xref>] 采用加权基因共表达网络分析(WGCNA)、蛋白质相互作用网络(PPI)和京都基因与基因组百科全书(KEGG)途径分析方法检测CCDC26的功能，发现CCDC26在AML新诊断和复发患者中的表达水平明显高于对照组。且CCDC26表达水平高的患者总体生存率较低。因此LncRNA-CCDC26可作为监测AML进展和预测临床转归的一种新的生物标志物。</p></sec><sec id="s8_2"><title>4.2. LncRNA XLOC_109948</title><p>LncRNA XLOC_109948在2017年由De Clara等 [<xref ref-type="bibr" rid="hanspub.44706-ref10">10</xref>] 首次报道，基因定位于性染色体上：ChrX：45，688，377-45，689，937，亚细胞定位：胞浆20%，核内80%。JY Zhou等 [<xref ref-type="bibr" rid="hanspub.44706-ref11">11</xref>] 经研究发现LncRNA XLOC_109948在AML患者骨髓和血清中的表达高于完全缓解的AML患者和健康人。AML患者达到CR时LncRNA XLOC_109948的表达显着降低。Etienne De Clara等 [<xref ref-type="bibr" rid="hanspub.44706-ref10">10</xref>] 研究也发现XLOC_109948的低表达预示着良好的预后，特别是对于NPM1突变的患者。在经Ara-C或全反式维甲酸处理的NPM1突变的OCI-AML3细胞中，瞬时转染针对XLOC_109948的GapmeR可促进细胞凋亡。Zhou JY等 [<xref ref-type="bibr" rid="hanspub.44706-ref11">11</xref>] 研究发现AML患者骨髓组织中LncRNA XLOC_109948的表达增高，但经化疗达到完全缓解后，LncRNA XLOC_109948表达水平明显下调。以上研究表明XLOC_109948可作为AML的新型生物标志物且其在药物敏感性中也起重要作用。</p></sec><sec id="s8_3"><title>4.3. LncRNA NEAT1</title><p>越来越多的研究阐明，LncRNAs作为竞争性内源RNAs (CeRNAs)与miRNAs结合，在疾病发展过程中影响基因表达。Song Fen等 [<xref ref-type="bibr" rid="hanspub.44706-ref12">12</xref>] 研究发现NEAT1上调抑制了AML细胞的生长、迁移和侵袭，但促进了AML细胞的凋亡。抑制CREB3调节因子可逆转NEAT1对AML细胞的作用。此外，NEAT1直接靶向miR-338-3p和miR-338-3p靶向CREBRF。NEAT1/miR-338-3p可通过调控CREBRF影响AML细胞的行为。NEAT1通过调控肿瘤细胞生长、迁移、侵袭、转移、上皮向间充质转化、干细胞样表型、化疗和放疗耐药相关基因的表达促进肿瘤的发生和发展 [<xref ref-type="bibr" rid="hanspub.44706-ref13">13</xref>]。</p></sec><sec id="s8_4"><title>4.4. LncRNA-CRNDE</title><p>Peixian Zhang等 [<xref ref-type="bibr" rid="hanspub.44706-ref14">14</xref>] 研究发现LncRNA CRNDE和LncRNA SNA CRNDE和LncRNAHG7可作为预测SCLM手术后OS和肿瘤复发的生物标志物。Y. WANG等 [<xref ref-type="bibr" rid="hanspub.44706-ref15">15</xref>] 发现急性髓系白血病和U937 (人组织细胞淋巴瘤细胞)细胞中LncRNA-CRNDE的表达明显高于非恶性血液病对照组。LncRNA-CRNDE的表达与临床髓系白血病的分类和总生存期有关。转染siRNA-CRNDE后，U937细胞增殖和克隆能力下降，凋亡增加(P &lt; 0.01)，细胞停滞在G0~G1期。同时，转染pcDNA-CRNDE后，U937细胞的增殖能力显著增强，表明LncRNA-CRNDE的表达可能在促进U937细胞增殖中起重要作用。</p></sec><sec id="s8_5"><title>4.5. HOXBAS3</title><p>HOXB-AS3位于染色体17q21.32上的人HOXB簇上，有八个转录变体，通过选择性剪接产生。Wenyang Jiang等 [<xref ref-type="bibr" rid="hanspub.44706-ref16">16</xref>] 发现HOXB-AS3在非小细胞肺癌组织和细胞中明显升高，敲除HOXB-AS3基因明显抑制了肺癌的进展，表明HOXB-AS3可成为肺癌治疗的有效靶点。Huai-Hsuan Huang等 [<xref ref-type="bibr" rid="hanspub.44706-ref17">17</xref>] 研究发现在急性髓细胞白血病中HOXBAS3诱导了一些与细胞周期进程和DNA复制有关的基因表达，从而促进了髓系细胞的增殖。并且HOXB-AS3高表达组的生存期短于HOXB-AS3低表达组。多因素分析表明，HOXBAS3的高表达是急性髓系白血病患者OS预后不良的独立因素。Dimitrios Papaioannou等 [<xref ref-type="bibr" rid="hanspub.44706-ref18">18</xref>] 也发现HOXB-AS3过表达导致白血病细胞增殖率增加。以上研究表明，HOXB-AS3可作为治疗高表达HOXB-AS3的AML患者的新靶点。</p></sec><sec id="s8_6"><title>4.6. LncRNA CCAT1</title><p>Lianxiang Chen等 [<xref ref-type="bibr" rid="hanspub.44706-ref19">19</xref>] 发现AML患者的LncRNA CCAT1较正常对照组升高，尤其是M4和M5亚型(粒单核细胞亚型)。我们进一步证明，CCAT1通过作为miR-155微RNA (MiRNA)的竞争内源性RNA (CERNA)来抑制髓系细胞分化和促进细胞增殖。C-Myc随后被证实是CCAT1 Cerna活性的下游靶点，并且对CCAT1调节AML的进展很重要，这表明CCAT1通过改变其靶向来调节miR-155的活性。Lianxiang Chen等 [<xref ref-type="bibr" rid="hanspub.44706-ref19">19</xref>] 研究发现CCAT1通过诱导或抑制HL-60细胞增殖，抑制单核细胞分化，促进HL-60细胞生长，揭示了LncRNA CCAT1在急性髓系白血病发生发展中的新机制，提示CCAT1的表达机制可作为急性髓系白血病治疗的一种有效策略。</p></sec><sec id="s8_7"><title>4.7. CASC15</title><p>CASC15在RUNX1易位的急性白血病中高表达，其在细胞中的表达导致细胞凋亡增加，造血系统植入率降低 [<xref ref-type="bibr" rid="hanspub.44706-ref20">20</xref>]。TIANYU HE等 [<xref ref-type="bibr" rid="hanspub.44706-ref21">21</xref>] 研究发线59% (48/82)的肝癌组织中CASC15的表达高于临近的正常组织，且CASC15的表达水平与恶性肿瘤的转移(P = 0.012)、肿瘤的大小(P = 0.037)和TNM分期(P = 0.013)显著相关。Kaplan-Meier生存曲线显示CASC15的高表达与肝癌患者的不良预后相关(P &lt; 0.05)。此外，还建立了CASC15基因敲除模型，该模型显示CASC15能明显抑制肝癌细胞的增殖、侵袭和迁移。CASC15基因敲除在体外也能诱导细胞凋亡，并能抑制体内肿瘤的生长。提示CASC15的高表达与预后不良有关。CAS15通过调节细胞凋亡和体内外细胞周期促进肝癌的增殖。此外，CASC15通过影响EMT相关途径促进细胞迁移和侵袭。这些结果表明，CASC15在肝癌中起癌基因的作用，是一种潜在的肝癌预测生物标志物。Sarah Grasedieck等 [<xref ref-type="bibr" rid="hanspub.44706-ref22">22</xref>] 研究发现从健康人骨髓制备的单链、非Poly-A富集的cDNA文库进行了测序(保存在GEO登录号#GSE98946)。在这个数据集中，CASC15的表达与髓系分化显著负相关，并且在成髓细胞中高度富集，这表明CASC15在维持干细胞特征(如未成熟表型和/或自我更新)方面发挥了作用。</p></sec></sec><sec id="s9"><title>5. 讨论</title><p>随着长链非编码RNA在实验研究中的发现越来越多，其在急性髓系白血病的诊断、分型、治疗和预后评估方面具有广阔的应用前景。研究人员还没有广泛地研究LncRNA在大型和临床控制的肿瘤数据集中的表达，也没有很好地了解LncRNA的功能，对LncRNA与AML关系的研究刚刚起步，长链非编码RNA在AML中的作用及其机制尚需进一步研究证实。在LncRNA与AML之间复杂的关系网络中，目前的研究结果只是冰山一角，尚且需要研究者进行更深入的研究。LncRNA作为肿瘤分子标志物以及潜在的治疗靶点有待进一步研究。LncRNA介导的治疗有望在AML的诊断、分型和治疗中得到更多应用，并逐步取得重要地位，也会为AML的靶向治疗奠定基础。</p></sec><sec id="s10"><title>文章引用</title><p>何冉冉,葛繁梅. 长链非编码RNA在急性髓系白血病发病机制中的研究进展Research Progress of Long Non-Coding RNA in the Pathogenesis of Acute Myeloid Leukemia[J]. 临床医学进展, 2021, 11(08): 3610-3615. https://doi.org/10.12677/ACM.2021.118528</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.44706-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Feng, Y., et al. (2018) Expression Profile Analysis of Long Non-Coding RNA in Acute Myeloid Leukemia by Microarray and Bioinformatics. Cancer Science, 109, 340-353. &lt;br&gt;https://doi.org/10.1111/cas.13465</mixed-citation></ref><ref id="hanspub.44706-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Vafadar, A., et al. (2019) Long Non-Coding RNAs as Epigenetic Regulators in Cancer. Current Pharmaceutical Design, 25, 3563-3577. &lt;br&gt;https://doi.org/10.2174/1381612825666190830161528</mixed-citation></ref><ref id="hanspub.44706-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Kino, T., et al. (2010) Noncoding RNA gas5 Is a Growth Arrest- and Starvation-Associated Repressor of the Glucocorticoid Receptor. Science Signaling, 3, ra8. &lt;br&gt;https://doi.org/10.1126/scisignal.2000568</mixed-citation></ref><ref id="hanspub.44706-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Terranova, R., et al. (2008) Polycomb Group Proteins Ezh2 and Rnf2 Direct Genomic Contraction and Imprinted Repression in Early Mouse Embryos. Developmental Cell, 15, 668-679. &lt;br&gt;https://doi.org/10.1016/j.devcel.2008.08.015</mixed-citation></ref><ref id="hanspub.44706-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Melo, C., et al. (2016) Long Non-Coding RNAs: Biomarkers for Acute Leukaemia Subtypes. British Journal of Haematology, 173, 318-320. &lt;br&gt;https://doi.org/10.1111/bjh.13588</mixed-citation></ref><ref id="hanspub.44706-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Chinen, Y., et al. (2014) 8q24 Amplified Segments Involve Novel Fusion Genes between NSMCE2 and Long Noncoding RNAs in Acute Myelogenous Leukemia. Journal of Hematology &amp; Oncology, 7, 68.  
&lt;br&gt;https://doi.org/10.1186/s13045-014-0068-2</mixed-citation></ref><ref id="hanspub.44706-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Hirano, T., et al. (2015) Long Noncoding RNA, CCDC26, Controls Myeloid Leukemia Cell Growth through Regulation of KIT Expression. Molecular Cancer, 14, 90. &lt;br&gt;https://doi.org/10.1186/s12943-015-0364-7</mixed-citation></ref><ref id="hanspub.44706-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Peng, W. and Jiang, A. (2016) Long Noncoding RNA CCDC26 as a Potential Predictor Biomarker Contributes to Tumorigenesis in Pancreatic Cancer. Biomedicine &amp; Pharmacotherapy, 83, 712-717.  
&lt;br&gt;https://doi.org/10.1016/j.biopha.2016.06.059</mixed-citation></ref><ref id="hanspub.44706-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Chen, C., et al. (2019) lncRNA-CCDC26, as a Novel Biomarker, Predicts Prognosis in Acute Myeloid Leukemia. Oncology Letters, 18, 2203-2211. &lt;br&gt;https://doi.org/10.3892/ol.2019.10591</mixed-citation></ref><ref id="hanspub.44706-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">De Clara, E., et al. (2017) Long Non-Coding RNA Expression Profile in Cytogenetically Normal Acute Myeloid Leukemia Identifies a Distinct Signature and a New Biomarker in NPM1-Mutated Patients. Haematologica, 102, 1718-1726.  
&lt;br&gt;https://doi.org/10.3324/haematol.2017.171645</mixed-citation></ref><ref id="hanspub.44706-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, J., et al. (2020) Expression and Clinical Significance of LcnRNA XLOC_109948 in Patients with Acute Myeloid Leukemia. Journal of Experimental Hematology, 28, 1539-1544.</mixed-citation></ref><ref id="hanspub.44706-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Feng, S., Liu, N., Chen, X.G., Liu, Y.F. and An, J.D. (2020) Long Non-Coding RNA NEAT1/miR-338-3p Axis Impedes the Progression of Acute Myeloid Leukemia via Regulating CREBRF. Cancer Cell International, 20, Article No. 112. &lt;br&gt;https://doi.org/10.1186/s12935-020-01182-2</mixed-citation></ref><ref id="hanspub.44706-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Dong, P., et al. (2018) Long Non-Coding RNA NEAT1: A Novel Target for Diagnosis and Therapy in Human Tumors. Frontiers in Genetics, 9, 471. &lt;br&gt;https://doi.org/10.3389/fgene.2018.00471</mixed-citation></ref><ref id="hanspub.44706-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Yi, M., et al. (2019) Downregulated lncRNA CRNDE Contributes to the Enhancement of Nerve Repair after Traumatic Brain Injury in Rats. Cell Cycle, 18, 2332-2343. &lt;br&gt;https://doi.org/10.1080/15384101.2019.1647024</mixed-citation></ref><ref id="hanspub.44706-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Wang, Y., Zhou, Q. and Ma, J.J. (2018) High Expression of lnc-CRNDE Presents as a Biomarker for Acute Myeloid Leukemia and Promotes the Malignant Progression in Acute Myeloid Leukemia Cell Line U937. European Review for Medical and Pharmacological Sciences, 22, 763-770.</mixed-citation></ref><ref id="hanspub.44706-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Jiang, W., et al. (2020) lncRNA HOXB-AS3 Exacerbates Proliferation, Migration, and Invasion of Lung Cancer via Activating the PI3K-AKT Pathway. Journal of Cellular Physiology, 235, 7194-7203. &lt;br&gt;https://doi.org/10.1002/jcp.29618</mixed-citation></ref><ref id="hanspub.44706-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Huang, H.H., et al. (2019) Long Non-Coding RNA HOXB-AS3 Promotes Myeloid Cell Proliferation and Its Higher Expression Is an Adverse Prognostic Marker in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. BMC Cancer, 19, 617. &lt;br&gt;https://doi.org/10.1186/s12885-019-5822-y</mixed-citation></ref><ref id="hanspub.44706-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Papaioannou, D., et al. (2019) The Long Non-Coding RNA HOXB-AS3 Regulates Ribosomal RNA Transcription in NPM1-Mutated Acute Myeloid Leukemia. Nature Communications, 10, 5351.  
&lt;br&gt;https://doi.org/10.1038/s41467-019-13259-2</mixed-citation></ref><ref id="hanspub.44706-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Chen, L., Wang, W., Cao, L.X., Li, Z.J. and Wang, X. (2016) Long Non-Coding RNA CCAT1 Acts as a Competing Endogenous RNA to Regulate Cell Growth and Differentiation in Acute Myeloid Leukemia. Molecules and Cells, 39, 330-336. &lt;br&gt;https://doi.org/10.14348/molcells.2016.2308</mixed-citation></ref><ref id="hanspub.44706-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Fernando, T.R., et al. (2017) The lncRNA CASC15 Regulates SOX4 Expression in RUNX1-Rearranged Acute Leukemia. Molecular Cancer, 16, 126. &lt;br&gt;https://doi.org/10.1186/s12943-017-0692-x</mixed-citation></ref><ref id="hanspub.44706-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">He, T., et al. (2017) Long Non-Coding RNA CASC15 Is Upregulated in Hepatocellular Carcinoma and Facilitates Hepatocarcinogenesis. International Journal of Oncology, 51, 1722-1730. &lt;br&gt;https://doi.org/10.3892/ijo.2017.4175</mixed-citation></ref><ref id="hanspub.44706-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Grasedieck, S., et al. (2020) The Long Non-Coding RNA Cancer Susceptibility 15 (CASC15) Is Induced by Isocitrate Dehydrogenase (IDH) Mutations and Maintains an Immature Phenotype in Adult Acute Myeloid Leukemia. Haematologica, 105, e448-e453. &lt;br&gt;https://doi.org/10.3324/haematol.2019.235291</mixed-citation></ref></ref-list></back></article>